A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer

This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC).

开始日期2024-08-26

申办/合作机构

BioNTech SE

NCT06449209 / Recruiting临床2期

A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer

This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) progressed on first- or second-line treatment (Cohort 2 and Cohort 3).

开始日期2024-08-05

申办/合作机构

BioNTech SE

IRCT20201203049585N3 / Suspended临床2/3期IIT

the effect of high power laser therapy on neuropathy induced by chemotherapy with taxane drugs in breast cancer patients

开始日期2023-08-23

申办/合作机构

Isfahan University of Medical Sciences

100 项与紫杉烷相关的临床结果

登录后查看更多信息

100 项与紫杉烷相关的转化医学

登录后查看更多信息

100 项与紫杉烷相关的专利（医药）

登录后查看更多信息

6,605

项与紫杉烷相关的文献（医药）

2024-12-31·Cancer Biology & Therapy

Association between the apoptotic effect of Cabazitaxel and its pro-oxidant efficacy on the redox adaptation mechanisms in prostate cancer cells with different resistance phenotypes

Article

作者: Eryilmaz, Isil Ezgi ; Egeli, Unal ; Cecener, Gulsah

Redox adaptation causes poor prognosis by adapting cancer cells to excessive oxidative stress. Previously, we introduced an oxidative stress-resistant metastatic prostate cancer (mPC) model (LNCaP-HPR) that redox adaptation reduced the effect of Cabazitaxel (Cab), the last taxane-derivative for metastatic castration-resistant PC (mCRPC). Whereas, we investigated for the first time whether there is an association between the altered apoptotic effect and pro-oxidant efficacy of Cab on the redox adaptation in PC cells with different phenotypes, including LNCaP mPC, LNCaP-HPR, C4-2 mCRPC, and RWPE-1 cells. Cab was shown pro-oxidant efficacy proportionally with the apoptotic effect, more prominent in the less aggressive LNCaP cells, by increasing the endogenous ROS, mitochondrial damage, and inhibiting nuclear ROS scavengers, p-Nrf2 and HIF-1α. However, the pro-oxidant and apoptotic effect was lower in the LNCaP-HPR and C4-2 cells, indicating that the drug sensitivity of the cells adapted to survive with more ROS was reduced via altered regulation of redox adaptation. Additionally, unlike LNCaP, Cab caused an increase in the p-NF-κB activation, suggesting that the p-NF-κB might accompany maintaining survival with the increased ROS in the aggressive PC cells. Moreover, the cytotoxic and apoptotic effects of Cab were less on RWPE-1 cells compared to LNCaP but were closer to those on the more aggressive LNCaP-HPR and C4-2 cells, except for the changing pro-oxidant effect of Cab. Consequently, this study indicates the variable pro-oxidant effects of Cab on redox-sensitive proteins, which could be a target for improving Cab's apoptotic effect more in aggressive PC cells.

2024-12-01·Biochemical and Biophysical Research Communications

Taxol-treatment alters endogenous TRPV1 expression and mitochondrial membrane potential in mesenchymal stem cells: Relevant in chemotherapy-induced pathophysiology

Article

作者: Das, Nilesh Kumar ; Mohanta, Sushama ; Goswami, Chandan

Microtubule-based chemotherapeutics, primarily Taxane-derived agents are still used as the major live-saving agents, yet have several side effects including serious loss of immune cells, bone density etc. which lowers the quality of life. This imposes the need to understand the effects of these agents on Mesenchymal Stem Cells (MSCs) in details. In this work we demonstrate that Taxol and Nocodazole affects the endogenous expression of TRPV1, a non-selective cation channel in MSCs. These agents also affect the status of polymerized Actin as well as Tyrosinated-tubulin, basal cytosolic Ca²⁺ and mitochondrial membrane potential (ΔΨm). Notably, pharmacological modulation of TRPV1 by Capsaicin or Capsazepine can also alter the above-mentioned parameters in a context-dependent manner. We suggest that endogenous expression of TRPV1 and pharmacological modulation of TRPV1 can be utilized to rescue some of these parameters effectively. These findings may have significance in the treatments and strategies with Microtubule-based chemotherapeutics and stem-cell based therapy.

2024-12-01·Current Problems in Cancer

Metaplastic breast cancer: Experience with ifosfamide based chemotherapy

Article

作者: Punia, R S ; Jose, Jesu Susan ; Dimri, Kislay ; Pandey, Awadhesh Kumar ; Dogra, Shifali ; Punia, RS ; Gupta, Nidhi

BACKGROUNDMetaplastic breast cancer (MPBC) is a rare variant of breast cancer and most treatment protocols are based on the guidelines for triple negative breast cancer. However, response to standard anthracycline and taxane based chemotherapy is poor. Published literature on use of ifosfamide based chemotherapy in the first line setting for MPBC is scarce.PATIENTS AND METHODSWe carried out this record based analysis on MPBC patients treated at our institute with the combination of ifosfamide and Adriamycin (IA) as first line therapy. Patients were analysed for the clinical and demographic profile; pathology and treatment details; and treatment outcomes.RESULTSFour patients who received IA chemotherapy were evaluated. Three of the four patients were postmenopausal. The median size of the tumor was 7.5 cm, only one patient had a heavy nodal burden and lung was the most common site of metastases seen in all three patients with metastatic disease. Pathology showed heterogenous, mixed histology with high grade tumors. All patients had triple negative tumors. All four patients underwent mastectomy and received IA chemotherapy as per standard doses. One patient had complete response, one had partial response and one patient progressed after 4 cycles of chemotherapy. The patient with localized disease continues to be disease free till date. Grade 3,4 neutropenia and grade 2 anemia was the most common chemotherapy related toxicity.CONCLUSIONThe response rates in MPBC with IA regimen appear to be similar to the currently used anthracycline-taxane combinations, with slightly more haematological toxicity. Ifosfamide and adriamycin regimen may be considered in MPBC patients as primary or salvage systemic therapy.

257

项与紫杉烷相关的新闻（医药）

2024-10-30

·今日头条

超级抗癌战士γ-δT细胞横扫多种癌症！肝癌、肺癌等患者已获益

每个人的身体内部都隐藏着一种“神秘力量”，时刻保护着我们远离癌症，这就是人体的免疫防御系统中至关重要的免疫细胞——“杀手”T细胞！近10年，三大基于T细胞的免疫疗法CAR-T、TCR-T、TILs已全部“修成正果”，获得批准上市。通过“强化”自己的免疫细胞清除全身肿瘤的梦想已成为现实，这些处于临床实验及上市的全新疗法已经帮助了世界各地成千上万的肿瘤患者。近期，一项由美国知名的莫菲特癌症中心主导的研究登上了国际知名期刊《Cell Reports Medicine》杂志上，揭露了一种新型的免疫细胞γ-δT细胞在33种不同癌症类型中的重要作用！研究人员说，尽管γ-δT仅占 T 细胞群的一小部分，但 γδ T 细胞能够识别更广泛的肿瘤抗原。最近的突破性发现表明，可以通过靶向治疗方法增强或挽救 γδ T 细胞的抗肿瘤功效。目前研究人员已经对覆盖33 种癌症类型的 γδ TCR 景观进行最准确、最全面的检查，这意味着，这是迄今为止人类癌症上最大的 γδ 克隆集合，通过深入了解γ-δT细胞在不同类型癌症中的作用，能够更精准地定制治疗方案，以提高患者的治疗效果！值得振奋的是，目前国内以及国际上已成功采用γ-δT细胞治疗肝癌、肺癌、食管癌、白血病等各类癌症，并取得了鼓舞人心的初步数据！ “超级抗癌战士”--γ-δT细胞横空出世！按T细胞表面TCR的类型分为两类：由α链和β链组成TCR的T细胞被称为αβT细胞，由γ链和δ链组成的T细胞被称为γδT细胞。 γδT 细胞是胸腺中发育的第一个 T 细胞谱系，这种细胞大约在 40 年前首次被发现。γδT 细胞仅占循环 T 细胞群的 1-10%，早在孕龄 12.5 周时即可在人类中观察到。然而，这些细胞一旦产生，就会在胸腺外扩增和成熟，目前研究证实，γδ T 细胞生物学的许多方面似乎非常适合癌症免疫治疗，包括对肿瘤组织的趋向性、非常广泛的识别潜力、对正常组织的高耐受性以及功能多效性。 γδT细胞的六大功能 γδT细胞可以产生大量的细胞因子和趋化因子来调节其他免疫(如 Treg)和非免疫细胞 γδT细胞可以为 B 细胞提供帮助，诱导树突细胞(DC)成熟 γδT细胞参与巨噬细胞募集 γδT 细胞对各种恶性肿瘤(如神经母细胞瘤)表现出不同程度的细胞溶解活性 γδT 细胞产生维持表皮完整性的生长因子 γδT细胞可以为 αBT细胞提供抗原 γδT 细胞在免疫治疗中四大的优势 1. γδT 细胞通过产生和释放可溶性因子来靶向直接以及间接杀伤肿瘤细胞，是天然的肿瘤杀手； 2. 不受限于MHC分子的递呈机制，异体用于肿瘤临床治疗的安全性已经被多次验证； 3. 与通用型UCAR-T不同，同种异体γδ T细胞或新抗原γδ T细胞不需要利用基因编辑技术敲除TCR基因来减少免疫排斥，因此可避免脱靶等诸多风险； 4. 至今多篇研究均表明γδ T细胞具备了良好的肿瘤浸润能力，对于克服一般CAR-T疗法的实体瘤障碍（例如：TME）具有极高的潜在能力。横扫多种癌症！肝癌、肺癌、食管癌、白血病等患者已获益近年来，γδ-T细胞在感染免疫、肿瘤免疫、AID等领域中所起的作用越来越受到广泛关注。国内外学者就其作用特点与机制做了大量研究，发现γδT细胞能执行复杂的功能，如免疫监视、免疫调节和发挥免疫效应等作用。特别是γδ-T 细胞可用于异体治疗的特质及其在实体瘤治疗中展现出卓越的潜力！ 01 全球首次完成γδ-T细胞治疗晚期肝癌、肺癌的3年期随访中国暨南大学生物医学转化研究院研究团队早在2017年-2018年在全球范围内率先完成了异体γδ T细胞临床研究。这项研究累计400多次异体γδ T细胞人体回输，临床观察达到130多例，初步证明了安全性和对实体癌初步有效。截至2021年9月，对8例晚期肝癌和10例晚期肺癌患者(接受细胞治疗次数均在5次或以上)进行了随访，从他们第一次输注异体γδ-T 细胞开始，目前这些患者的生存时间中位数为42.4个月(范围为30-50个月)！幸运的是，一位参加临床试验的胆管癌（IV 期）患者，之前接受了肝移植，随后出现了复发性纵隔淋巴结转移，在接受同种异体 γδ T 细胞治疗，积极调节患者的外周免疫功能，消除肿瘤活性，改善生活质量，延长患者寿命。经过 8 次 γδ T 细胞治疗后，他的淋巴结大小显著减小，活性降低，得到了完全控制。值得一提的是，这是全球首次完成对接受异体γδ-T细胞治疗晚期肝癌、肺癌的3年期随访。在国际上，率先证明同种异体γδ T细胞治疗在临床使用的安全性，对肝癌与肺癌展示了初步有效，并显著改善晚期肿瘤患者生活质量与免疫状态。 02 过继性γδT细胞移植单独或联合化疗治疗晚期食管癌 2021年，日本东京大学医院发表了一项在使用铂类、5-氟尿嘧啶和紫杉烷治疗后，复发性或转移性食管癌 (r/mEC) 患者中接受过继性 γδT 细胞疗法的 1 期试验结果。结果显示，26 名患者接受了 γδT 单药治疗。γδT 细胞治疗未发生严重不良事件。中位总生存期为 5.7 个月，中位无进展生存期为 2.4 个月。18 名患者接受了化疗联合γδT细胞。中位总生存期为 13.4 个月，中位无进展生存期为 4.0 个月。客观缓解率和疾病控制率分别为 39% 和 78%。研究人员认为，对于复发性或转移性食管癌患者，无论是否联合化疗，使用 γδT 细胞免疫疗法都是安全可行的。γδT 细胞联合化疗观察到了生存益处。 03 100%患者肿瘤细胞消退1年！γ-δT细胞为白血病带来新生机 2024年6月13日，在第49届欧洲血液学协会（EHA）年会上，公布了一款名为“INB-100”的抗癌新星γδ T细胞治疗的卓越临床数据，全部入组患者在接受γδ T细胞治疗后均，缓解率高达100%，且完全完全缓解状态持续长达1年之久！而既往接受造血干细胞移植等传统治疗的患者，一年内的率则高达50%。更为惊喜的是，其中3例高危白血病患者已经无癌生存35个月以上（近3年）！本研究首次证明了单倍体匹配同种异体或供体衍生细胞治疗，在365周的内部持续性和持久性！为高危或阻断性AML和其他血液系统恶性肿瘤患者提供了持久的无稳定性生存期，这对恶性肿瘤患者而言，无疑是巨大的福音。免疫疗法遍地开花！有望成为战胜癌症的终极武器！近年来，细胞治疗为恶性肿瘤、某些传染病和遗传病等难治性疾病患者带来了新的希望，并在美欧日等发达国家以多种方式开始进入临床应用，我国医疗机构也开展了大量临床研究，患者希望接受高质量细胞治疗的呼声日益增高。政府也在规范并加快细胞治疗科学发展，并允许临床研究证明安全有效的体细胞治疗项目经过备案在相关医疗机构进入转化应用，相关的临床试验也正在开展。 γ・ΔT细胞作为细胞毒性T细胞的另一个类型，是攻击癌细胞的另一个主要力量，成熟的细胞毒性T细胞受抗原刺激后，分化为效应细胞毒性T细胞和记忆细胞毒性T细胞。前者能特异性杀伤带抗原的靶细胞，如移植细胞、肿瘤细胞及受微生物感染的细胞等。γ・ΔT细胞用于以肺癌和多发性骨髓瘤为首的各种各样的癌症。中国，日本，美国等多家权威医院进行了临床研究，成果作为论文已经发表在国际期刊，是一种值得期待的治疗方法。想寻求γδT细胞等新一代新兴抗癌新帮助的病友，可将病历提交至全球肿瘤医生网医学部进行初步评估或申请免疫专家会诊。同时需要提醒病友，肿瘤的治疗一定是依托于权威医院及权威专家的正规治疗，在采取常规治疗手段（手术、放疗、化疗）治疗后，根据自身的经济情况，辅助免疫治疗技术等综合疗法，达到巩固治疗，预防复发，提高生活治疗，延长生存期的目的，最终取得抗癌成功。如果大家想全面了解自身的免疫状态或相关的免疫疗法，请致电医学部或加入免疫治疗医患交流群。

细胞疗法免疫疗法

2024-10-29

·EndPoints

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Just five months after closing its $2.9 billion deal for MorphoSys, Novartis has recorded an $800 million impairment on the acquisition after a review of “certain clinical trial data,” the company said in its third-quarter earnings report . A company spokesperson confirmed that the review was triggered by pelabresib, an oncology candidate at the center of the MorphoSys buyout. Novartis shared Tuesday that it’s expecting a delayed regulatory submission for pelabresib, as it needs to follow patients longer to assess concerns about emergent malignancies. The company had initially hoped to file for approval in myelofibrosis this year. Emergent malignancies in patients treated with pelabresib were first reported by STAT earlier this year. Novartis will “look at the data over the course of next year,” and assess the potential need for additional studies, CEO Vas Narasimhan said during its Q3 earnings call with the media. Novartis also disclosed three Phase 2 pipeline cuts Tuesday: a BCMA cell therapy called durcabtagene autoleucel or PHE885 in multiple myeloma; XXB750 in hypertension and heart failure; and an IL-17 inhibitor subbed CMK389 in pulmonary sarcoidosis. Overall, Barclays analysts said Novartis had a “strong” quarter. The company raised its end-of-year guidance, with Narasimhan saying its “pure-play” strategy is starting to pay off. While executives previously expected net sales growth in the high single digits to low double digits, Novartis now says the low end of that range will be in the double digits. “The changes we’ve made to become a focused, pure-play company focused on key therapeutic areas, focused on key geographies, is really working,” Narasimhan told reporters. Elsewhere, Narasimhan also fielded a variety of questions about Novartis’ new structure, legal strategy and manufacturing capacity: On the company’s reorganization: It’s been roughly two years since Novartis announced a global restructuring that impacted thousands of positions and involved the spinout of generics unit Sandoz. The company said it completed its transformation in November 2023, though “additional streamlining” this year brought some cuts on the development side. Narasimhan said Novartis is “always going to be fine-tuning at a low level, but we don’t foresee any other large changes at this time.” On radioligand supply: Novartis applied for a label expansion last quarter to bring Pluvicto into the pre-taxane setting for patients with metastatic castration-resistant prostate cancer. But despite recent shortage concerns across the radiopharma space, Narasimhan said Novartis’ manufacturing plans will enable not only the supply of Pluvicto, but also “a very large pipeline of radioligand therapies moving forward.” He added that Novartis’ supply has been “unconstrained for most of this year,” with the ability to produce volumes that support $7 billion to $8 billion-plus in sales. The company has plans to expand its Indianapolis site, and is putting up new sites in California, China and Japan. On the Inflation Reduction Act and a recent court loss: A New Jersey federal court recently rejected Novartis’ legal challenge to the IRA. The company has appealed, though Narasimhan said it’s “difficult to say” whether Novartis’ case or cases brought by other drugmakers will conclude before negotiated prices take effect in 2026. For now, the CEO said Novartis is pushing for legislative changes, including around a provision that calls for negotiations to occur sooner for small molecule drugs than for biologics. “We are operating under the assumption that we need to work under the rules of the law and rather focus on trying to educate policymakers,” he said. On generic entry: Novartis said it expects generic rivals to Tasigna, Promacta and Entresto to hit the US market in mid-2025. “That will certainly be a headwind we’ll face in the second half of 2025,” Narasimhan said. “We still expect good growth next year, both on the top and bottom line.” Editor’s note: This story has been updated to include comment from Novartis on the MorphoSys impairment.

临床2期细胞疗法并购

2024-10-28

·诺华集团

关注男性健康， RLT为晚期前列腺癌带来精准治疗新希望

10月28日是“世界男性健康日”，也是我国第25个“中国男性健康日”。今年的主题 “人口发展高质量，男性健康全周期”彰显了男性健康之于人口发展及全生命周期健康管理的重要性，其中特别值得关注的是男性前列腺健康问题，不仅直接关乎个人生存与家人生活质量，更会带来不容忽视的社会影响。在全球范围内，前列腺癌已经成为威胁男性健康最常见的恶性肿瘤之一。最新发布的《全球癌症流行病学报告（2024）》数据显示，2022年前列腺癌发病率及死亡率均分别排在全部恶性肿瘤第四位和第六位，是男性第二常见恶性肿瘤，死亡人数排在男性恶性肿瘤第五位1。由国家癌症中心发布的中国恶性肿瘤疾病负担情况2显示，2022年中国前列腺癌新发病例数和新增死亡病例数分别为13.42万人和4.75万人，较2000~2018年呈上升趋势，给越来越多的患者和家庭造成巨大影响，带来精神和经济上的巨大负担。前列腺癌高发于老年男性群体，随着我国老龄化的加剧，未来发病形势更为严峻。特别值得警惕的是，我国大多数前列腺癌患者在初诊时就已经出现转移。多中心数据分析结果3表明，中国初诊患者中仅1/3的患者表现为临床局灶性前列腺癌，多数患者已经处于中晚期。在北京、上海和广州进行的一项研究结果显示，国内新诊断的前列腺癌患者中，54%的患者在诊断时已发生远处转移（包括骨和腹部器官转移）4。发生远处转移的患者，5年相对生存率从未转移患者的80%降至30%5，无进展生存时间仅为未转移患者的一半6。对于大部分前列腺癌患者，不仅要承受疾病带来的身体痛苦，更要在极为有限的治疗手段中苦苦寻觅希望。同时社会传统认知对前列腺疾病及治疗有损男性尊严的错误认知，也让很多患者选择沉默或是消极对待。漫长的病程如同一场看不到尽头的马拉松，复杂的疾病情况往往让他们心力交瘁。前列腺癌病程长，疾病情况复杂，内分泌治疗是前列腺癌常用的治疗方式，通过降低男性激素水平，如睾酮，来抑制前列腺癌的生长。去势治疗联合抗雄激素治疗通常是首选的治疗方法。然而，随着时间的推移，一些转移性前列腺癌患者会出现去势抵抗性，即去势治疗不再有效，需要新的治疗手段控制肿瘤生长，延长生存期。当出现去势抵抗，对于患者而言，只能在迷茫与煎熬中，艰难地度过每一个日夜。同时随着疾病进入转移性去势抵抗性前列腺癌（mCRPC）阶段，肿瘤具有高侵袭性且预后较差，中位生存时间仅有17.5～34.7个月7，超过70%的mCRPC患者会出现骨转移8。 “在接受内分泌治疗后，再次出现了复发和骨转移，之后换药，又加入化疗开始二线治疗。但治疗带来的副作用难以缓解，让我怀疑自己是不是已经无药可治，心里感觉特别绝望和无助……”对很多mCRPC阶段的患者和家属来说，由于一线治疗失效，他们往往需要换用二线、三线治疗方案，而病情复发和发展所带来的挫败感和无助感，给患者和家属造成了巨大的心理压力。对于他们而言，无时无刻不在期盼更有效的突破创新疗法问世，能让他们再次感受生命的活力与美好。在内分泌治疗、手术治疗、化疗、放疗等传统治疗方案之外，近年来利用核素精准打击癌症的创新放射配体疗法（RLT）在肿瘤治疗领域受到越来越多的关注，特别是以靶向PSMA的RLT创新药物，目前已经在治疗前列腺癌的临床实践中证明了其疗效和安全性。放射配体疗法（RLT）所采用的放射配体，含有可精准识别和结合肿瘤细胞的靶向配体，以及用于杀伤肿瘤的放射性核素——当靶向配体与癌细胞结合后，治疗用放射性核素直接向癌细胞或其附近区域发出射线，从而破坏癌细胞。治疗用放射性核素射线范围短，因此这种治疗方法对病灶周围组织造成的损伤有限。放射配体疗法可精准识别和杀伤癌细胞靶向配体可将治疗用放射性核素导向癌症细胞，这种精准杀伤肿瘤细胞、降低其它组织损伤、有效避免耐药的特性，让RLT疗法赢得了“魔法核弹”的美名。这种疗法的问世，解决了mCRPC患者缺乏有效治疗手段的难题。基于多个关键III期临床试验的结果：在晚期PSMA阳性mCRPC患者的治疗发现，可显著延长影像学无进展生存期和总生存期。同时，放射配体疗法可提高曾接受过ARPI*的治疗、尚未接受过基于紫杉烷化疗的PSMA阳性mCRPC患者的放射学无进展生存期（rPFS），以及完全缓解比例9，在生活质量和疼痛方面均有明显改善，这进一步展现出了应用于早期前列腺癌治疗的巨大潜力。中国医学科学北京协和医院核医学科主任霍力教授此前在接受采访时表示，随着核医学诊疗一体化的发展，以放射配体疗法为代表的放射性药物极有希望成为肿瘤治疗的新支柱，改变癌症治疗的未来。目前，诺华已在中国启动多项 RLT 的临床研究，涵盖后线和前线前列腺癌治疗及其他早期管线产品，也积极推动RLT的引入与临床应用10。此外，国内多个学会也发起制定了177Lu-PSMA-617放射性配体疗法治疗前列腺癌的临床实践专家共识11，为放射配体疗法后续的中国临床应用奠定了坚实的基础。在全社会共同提升对男性健康关爱的大背景下，诺华以“承诺中华”为己任，正努力将放射配体疗法（RLT）的技术、标准、经验、产能带入中国，全力推动放射配体疗法在中国的落地普及。与此同时，诺华也将与产、学、研各界以及国内患者组织展开广泛合作，持续关注男性健康，为更多前列腺癌患者及家属带来安全、有效的治疗选择与服务，为改善和守护中国男性健康贡献力量。 * 雄激素受体通路抑制剂 — 参考文献 — （滑动查看更多） 1.Volume 74Issue 1CA: A Cancer Journal for Clinicians pages: 8-9 January 17, 2024 2.HAN B F, ZHENG R S, ZENG H M, et al. Cancer incidence and mortality in China, 2022 [J]. J Natl Cancer Cent, 2024, 4(1): 47-53. 3.中国抗癌协会泌尿男生殖系统肿瘤专业委员会前列腺癌学组. 前列腺癌筛查中国专家共识(2021年版) [J]. 中国癌症杂志, 2021, 31(5): 435-440. 4.马春光，叶定伟，李长岭，等．前列腺癌的流行病学特征及晚期一线内分泌治疗分析[J]．中华外科杂志， 2008， 46( 12): 921- 925. DOI: 10.3321/j.issn:0529-5815.2008.12.012. 5.SiegelRL, MillerKD, JemalA. Cancer statistics, 2018[J]. CA Cancer J Clin, 68( 1): 7- 30. DOI: 10.3322/caac.21442. 6.RossRW, XieW, ReganMM, et al. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate－specific antigen level, and prior ADT exposure with duration of ADT effect[J]. Cancer, 2008, 112( 6): 1247- 1253. DOI: 10.1002/cncr.23304. 7.Chen JR, Zhang YW, Zhang XM, et al. Comparison of systemic treatments for metastatic castration-resistant prostate cancer after docetaxel failure: a systematic review and network meta-analysis[J]. Front Pharmacol, 2022, 12:789319. DOI:10.3389/fphar.2021.789319. 8.中国抗癌协会泌尿男生殖系统肿瘤专业委员会. 前列腺癌骨转移和骨相关疾病临床诊疗专家共识(2021 版)[J]. 中华肿瘤杂志, 2021, 43(10):1016-1026. DOI:10.3760/cma. j.cn112152-20210714-00513. 9.AUA 2024: Paradigm-Shifting, Practice-Changing Clinical Trials in Urology: PSMAfore: Efficacy of 177Lu-PSMA-617 Versus ARPI Change in Taxane-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer by Pre-Randomization ARPI. Retrieved May 4, 2024, from https://www.urotoday.com/conference-highlights/aua-2024/aua-2024-prostate-cancer/151727-aua-2024-paradigm-shifting-practice-changing-clinical-trials-in-urology-psmafore-efficacy-of-177lu-psma-617-versus-arpi-change-in-taxane-naive-patients-with-metastatic-castration-resistant-prostate-cancer-by-pre-randomization-arpi.html 10.国家药品监督管理局药品审评中心 11.中国抗癌协会肿瘤核医学专业委员会.中国癌症杂志,2024,34(7):702-714; 中国临床医学杂志

临床结果临床研究临床终止

100 项与紫杉烷相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性肺癌	临床3期	美国	Bristol Myers Squibb Co.	2005-02-16
复发性肺癌	临床3期	加拿大	Bristol Myers Squibb Co.	2005-02-16
非霍奇金淋巴瘤	临床3期	荷兰	Bayer AG	2002-02-28
非霍奇金淋巴瘤	临床3期	英国	Bayer AG	2002-02-28
非霍奇金淋巴瘤	临床3期	加拿大	Bayer AG	2002-02-28
非霍奇金淋巴瘤	临床3期	德国	Bayer AG	2002-02-28
乳腺癌	临床3期	德国	Martin-Luther-Universität Halle-Wittenberg	2002-01-31
乳腺癌	临床3期	德国	Martin-Luther-Universität Halle-Wittenberg	2002-01-31
非霍奇金淋巴瘤	临床2期	法国	Bayer AG	2002-02-28
非霍奇金淋巴瘤	临床2期	美国	Bayer AG	2002-02-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO2024 人工标引	N/A	三阴性乳腺癌新辅助	267	Carboplatin (AUC 4) every 2 weeks plus taxane (standard dose)	(範齋齋夢衊憲襯鹹網夢) = 壓膚鬱糧衊鑰餘範鏇鹹願艱鬱顧願夢簾鹹膚淵 (廠構獵醖衊簾鹹鑰艱鹽 ) 更多	积极	2024-09-16
				Carboplatin (AUC 5) every 3 weeks plus taxane	(範齋齋夢衊憲襯鹹網夢) = 獵鹽願願獵鏇顧簾窪選願艱鬱顧願夢簾鹹膚淵 (廠構獵醖衊簾鹹鑰艱鹽 ) 更多
ASCO2023	N/A	复发性头颈部鳞状细胞癌	444	Platinum/5FU/pembrolizumabPlatinum/5FU/pembrolizumab	(獵鬱願夢廠製糧獵繭鏇) = 壓範繭襯獵鑰製願網獵壓齋襯淵衊網構觸淵願 (鬱襯膚鹹範夢壓鹹壓蓋 ) 更多	-	2023-05-31
				Platinum/taxane/pembrolizumabPlatinum/taxane/pembrolizumab	(獵鬱願夢廠製糧獵繭鏇) = 壓憲膚餘窪顧餘選範醖壓齋襯淵衊網構觸淵願 (鬱襯膚鹹範夢壓鹹壓蓋 ) 更多
WCLC2022	N/A	晚期非小细胞肺癌	467	Taxane monotherapy	(積繭窪齋網鑰鏇觸範窪) = 蓋餘繭廠膚繭壓夢淵築廠膚選築糧遞製遞積廠 (觸蓋選觸艱鏇醖簾繭鹽, 8.1 ~ 11.2)	-	2022-08-06
				Taxane-containing combination	(積繭窪齋網鑰鏇觸範窪) = 選鬱憲鏇夢憲衊襯壓鹹廠膚選築糧遞製遞積廠 (觸蓋選觸艱鏇醖簾繭鹽, 7.5 ~ 9.6)
ESMO_IO2021	N/A	转移性非小细胞肺癌	110	Taxane regimen	範鏇選製齋襯構鏇窪製(鏇鏇顧積糧獵襯選壓願) = 廠繭鹹艱繭衊淵淵構艱獵鏇遞選獵餘鏇範襯範 (製衊鹹選願願觸齋餘築, 2.7 ~ 4.8)	-	2021-12-09
WCLC2021	N/A	肺炎巩固	119	Taxane-based chemotherapy regimen	(窪願構衊衊憲遞網願壓): OR = 1.67 (95% CI, 0.72 ~ 3.88), P-Value = 0.23	-	2021-09-08
				Non-taxane-based chemotherapy regimen
ASCO2020	N/A	乳腺癌	40	Taxane monotherapy	鏇窪鹹願願簾構餘鏇網(獵膚遞蓋網選構願鑰餘) = 夢構製壓壓窪顧願鹽夢艱觸醖簾蓋選鏇選網築 (糧糧衊艱齋築餘鏇鑰鏇 )	-	2020-05-25
MNCCTN (ASCO2020)	N/A	-	-	Paclitaxel	(淵願鑰餘憲鬱簾鹹觸衊) = 範齋壓鹽壓簾艱構窪製夢築獵衊糧鬱糧餘壓顧 (鏇選壓製窪壓糧積餘鑰 ) 更多	积极	2020-05-25
				Docetaxel	齋憲壓繭醖衊簾遞夢範(鹽窪鏇製構製鏇膚範製) = 顧壓鹽鹽鹹鹽衊鑰觸淵獵積構衊憲願窪艱繭築 (範鹽淵糧餘襯廠醖構積, 25.7% ~ 70.2%)
ASCO_GU2019	N/A	阴茎肿瘤	-	Taxane combination chemotherapy regimens	(廠鏇壓襯齋簾襯艱選醖) = 網壓蓋廠淵蓋選選網窪獵遞遞網選壓憲願鏇築 (齋蓋壓範醖窪範醖憲鹹 ) 更多	积极	2019-02-26
				Non-taxane regimens	(廠鏇壓襯齋簾襯艱選醖) = 蓋鹽鹹製憲選獵糧廠糧獵遞遞網選壓憲願鏇築 (齋蓋壓範醖窪範醖憲鹹 ) 更多
ASCO2016	N/A	食管鳞状细胞癌	179	Taxane-based chemoradiotherapy	(窪淵醖製憲齋鬱願獵顧) = 鹽廠餘夢築蓋觸簾壓繭範顧選鹹齋製製餘衊獵 (觸蓋獵築簾遞艱觸顧顧 ) 更多	积极	2016-05-20
				Fluorouracil-based chemoradiotherapy	(窪淵醖製憲齋鬱願獵顧) = 觸憲壓顧鬱膚顧願築製範顧選鹹齋製製餘衊獵 (觸蓋獵築簾遞艱觸顧顧 ) 更多
ASCO2014	N/A	转移性乳腺癌	938	Taxane rechallenge as first line treatment	(構製獵願鹽壓鬱顧壓廠) = 範衊憲膚齋齋鑰選淵鹹醖醖蓋鏇簾遞簾窪膚蓋 (鑰艱廠構範蓋憲積糧鏇 )	-	2014-05-20